Zanubrutinib vs. acalabrutinib in B-cell malignancies: An adverse event-based economic analysis
Zanubrutinib (zanu) versus acalabrutinib (acala) in B-cell malignancies: an adverse event (AE)-based economic analysis
GPT: The Next Frontier in Health Economic Modeling?
Effective Data Visualization Techniques for Presenting Scenario Analysis Results in Health Economic Models
Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden
Issues, Challenges and Opportunities for Economic Evaluations of Orphan Drugs in Rare Diseases: An Umbrella Review

Cost-effectiveness of therapeutics for COVID-19 patients: a rapid review and economic analysis

Cost-Effectiveness Analysis of Pembrolizumab for First-Line Treatment in Patients with Persistent, Recurrent, and Metastatic Cervical Cancer in the United States: Results from the Final Analysis of Trial

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy, with or without Bevacizumab for the First-Line Treatment of Pd-L1-Positive Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in France

Unraveling Modeling Challenges in the Economic Evaluations of Gene Therapies: A Global Review
